IBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD Horizon
HIBD Horizon

To finish · 22/22

The final word

Where we come from, where we are now, and why I have so much hope.

1996

No biologics

Steroids, mesalazine, azathioprine… and surgery.

1999

The 1st biologic

Infliximab, authorised in Europe, in widespread use in France from the mid-2000s.

2014 → 2026

The acceleration

10 new molecules in 12 years.

Tomorrow

The age of AI

Dozens of molecules in trials, drugs designed faster.

13molecules authorised in Europe since 1999
6different families of treatment
15 monthson average between two new treatments since 2014

When I was diagnosed, Crohn's was frightening. And 30 years ago, there was good reason: in 1996, there were no biologics. Patients only had steroids, mesalazine, azathioprine… and surgery when nothing else worked.

Then everything changed with infliximab, the first biologic: authorised in Europe in 1999, at first reserved for the most severe forms, it really came into widespread use in France in the mid-2000s. For the first time, we could aim for real remission, and even heal the bowel wall.

Since then, everything has been speeding up: 13 molecules authorised in Europe, from 6 different families, 10 of them since 2014. That's a new treatment every 15 months on average! And dozens more are in trials all over the world. If one treatment doesn't work for you, there is almost always another option.

And I sincerely believe the best is yet to come. Artificial intelligence is starting to transform research: it helps us understand diseases faster, design drugs in a few months instead of several years, and perhaps one day spot the disease before it even starts.

So yes, Crohn's and UC are still difficult diseases. But I have never had as much hope as I do today. Take care of yourselves, stay in charge of your disease, and never give up: the best is ahead of us.

The author, living with Crohn's for more than 20 years